A multi-center study to determine genetic variations in the fusion gene of respiratory syncytial virus (RSV) from children <2 years of age in the U.S
- PMID: 35792350
- DOI: 10.1016/j.jcv.2022.105223
A multi-center study to determine genetic variations in the fusion gene of respiratory syncytial virus (RSV) from children <2 years of age in the U.S
Abstract
The fusion (F) protein of respiratory syncytial virus (RSV) is the major target of immunoprophylactic monoclonal antibodies (mAbs) and vaccines. Recently reported mutations in F gene antigenic sites can vary among RSV types A and B. To further understand mutations in RSV F proteins, we performed subtyping and F gene sequencing on 400 RSV-positive respiratory samples collected at four pediatric hospitals within the United States from children under 2 years old between 2018 and 2020. RSV B was predominant in 2018-2019 and RSV A in 2019-2020 (55.5% and 85.5% respectively). Compared to the reference sequence, all RSV B samples had at least one antigenic polymorphism with the most changes at sites AM14/V (100%) and Ø (93.3%) followed by II (5.8%), IV (3.9%), and p27 (2.9%). The most frequent mutations among RSV B for AM14/V site were in L172Q (100%), S173L (100%), and K191R (95.2%) while for Ø site they were in I206M (93.3%) and Q209R (93.3%). Conversely, polymorphisms were observed in only 15.3% of RSV A samples overall, specifically at antigenic sites p27 (5.9%), IV (3.0%), II (2.5%), AM14/V (2.0%), I (2.0%), and Ø (0.5%). Among RSV A cases, T122A at p27 (n = 10) and S276N at II (n = 3) were the most common substitution sites. S276N at site II was found in both RSV types. Although polymorphisms in F proteins of RSV B were more common than those in RSV A samples, changes in both subtypes were observed in key F antigenic sites which could potentially impact the efficacy of mAb therapies and vaccines.
Keywords: Antigenic sites; Children; Fusion protein; Respiratory syncytial virus.
Copyright © 2022. Published by Elsevier B.V.
Similar articles
-
Sequence variability of the respiratory syncytial virus (RSV) fusion gene among contemporary and historical genotypes of RSV/A and RSV/B.PLoS One. 2017 Apr 17;12(4):e0175792. doi: 10.1371/journal.pone.0175792. eCollection 2017. PLoS One. 2017. PMID: 28414749 Free PMC article.
-
Global Molecular Epidemiology of Respiratory Syncytial Virus from the 2017-2018 INFORM-RSV Study.J Clin Microbiol. 2020 Dec 17;59(1):e01828-20. doi: 10.1128/JCM.01828-20. Print 2020 Dec 17. J Clin Microbiol. 2020. PMID: 33087438 Free PMC article.
-
Respiratory syncytial virus prefusogenic fusion (F) protein nanoparticle vaccine: Structure, antigenic profile, immunogenicity, and protection.Vaccine. 2019 Sep 24;37(41):6112-6124. doi: 10.1016/j.vaccine.2019.07.089. Epub 2019 Aug 12. Vaccine. 2019. PMID: 31416644
-
Clinical Potential of Prefusion RSV F-specific Antibodies.Trends Microbiol. 2018 Mar;26(3):209-219. doi: 10.1016/j.tim.2017.09.009. Epub 2017 Oct 17. Trends Microbiol. 2018. PMID: 29054341 Review.
-
Human respiratory syncytial virus: pathogenesis, immune responses, and current vaccine approaches.Eur J Clin Microbiol Infect Dis. 2018 Oct;37(10):1817-1827. doi: 10.1007/s10096-018-3289-4. Epub 2018 Jun 6. Eur J Clin Microbiol Infect Dis. 2018. PMID: 29876771 Review.
Cited by
-
Resurgence of respiratory syncytial virus with dominance of RSV-B during the 2022-2023 season.Front Microbiol. 2024 Apr 2;15:1376389. doi: 10.3389/fmicb.2024.1376389. eCollection 2024. Front Microbiol. 2024. PMID: 38628867 Free PMC article.
-
Whole-Genome Sequencing and Genetic Diversity of Human Respiratory Syncytial Virus in Patients with Influenza-like Illness in Sicily (Italy) from 2017 to 2023.Viruses. 2024 May 26;16(6):851. doi: 10.3390/v16060851. Viruses. 2024. PMID: 38932144 Free PMC article.
-
Evolving Epidemiology of Pediatric Respiratory Syncytial Virus (RSV) Cases Around COVID-19 Pandemic: Impact and Clinical Insights, Retrospective Cohort Study.J Epidemiol Glob Health. 2024 Jun;14(2):319-326. doi: 10.1007/s44197-024-00218-4. Epub 2024 Apr 4. J Epidemiol Glob Health. 2024. PMID: 38573464 Free PMC article.
-
Differences Between RSV A and RSV B Subgroups and Implications for Pharmaceutical Preventive Measures.Infect Dis Ther. 2024 Aug;13(8):1725-1742. doi: 10.1007/s40121-024-01012-2. Epub 2024 Jul 6. Infect Dis Ther. 2024. PMID: 38971918 Free PMC article. Review.
-
All Eyes on the Prefusion-Stabilized F Construct, but Are We Missing the Potential of Alternative Targets for Respiratory Syncytial Virus Vaccine Design?Vaccines (Basel). 2024 Jan 18;12(1):97. doi: 10.3390/vaccines12010097. Vaccines (Basel). 2024. PMID: 38250910 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical